August 23, 2017 / 12:21 PM / 2 years ago

BRIEF-Intra-Cellular Therapies announces positive regulatory update on schizophrenia program

Aug 23 (Reuters) - Intra-cellular Therapies Inc

* Intra-Cellular Therapies announces positive regulatory update on schizophrenia program

* Intra-Cellular Therapies Inc- ‍U.S. FDA has informed company that FDA has completed its review of company’s responses to requests from FDA​

* Intra-Cellular Therapies-‍requests from FDA relate to information regarding some findings in nonclinical toxicology studies of lumateperone in animals

* Intra-Cellular Therapies-‍FDA agrees that co presented adequate data to support position metabolic pathway in animal species is distinctive from humans​

* Intra-Cellular Therapies-‍moving forward with long-term safety study of lumateperone, intends to submit NDA for treatment of schizophrenia by mid-2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below